of this comparison is easier to establish, especially for Braille readers about whom there is little information on pseudoword processing.

Auditory stimuli had the same characteristics as the visual/tactile stimuli except that the non-words were reversed words. During half of the word-presentation conditions, we presented abstract words (low imageability 250–400 [according to the Medical Research Council psycholinguistic database]) and concrete words (high imageability 550–700). The task in all conditions was a feature-detection task involving incidental word processing as described previously. Targets were ascenders in the visual conditions (for example in the letters I, A and t), one or more raised dot number 6 (the right lower dot) in the Braille words, and a short tone in the auditory conditions. The use of implicit processing allowed us to match attentional set between conditions and to monitor performance. Words and non-words were matched for the number of characters (5.6 ± 1.3) syllables (1.7 ± 0.5) and occurrences of targets (430%). Responses were made by pressing a button with the thumb of the right hand. The instructions were: "Read/listen to the word and if you find/hear a target, press the button." Target detection exceeded 85% in all groups. The mean reaction time for visual/tactile presentation was 552 ± 116 ms for the sighted group, 1605 ± 281 ms for the congenitally blind group and 1809 ± 364 ms for the late-blind group.

Received 6 April; accepted 27 May 1998.
In mice, the early phase of pain behaviour was blocked when anandamide was injected into the paw together with formalin, whereas both phases were blocked by the synthetic cannabinoid agonists WIN-55212-2 and HU-210 (Fig. 1a; data not shown). These analgesic effects were prevented by systemic administration of the CB1 antagonist SR141716A (Fig. 1a), but not of the CB2 antagonist SR144528 (Fig. 1a)\(^6\) or of the opioid antagonist naloxone (0.2 mg per kg, intravenously; data not shown). The lack of effect of anandamide on late-phase pain behaviour may be explained by the short lifespan of this compound, which undergoes rapid biological inactivation in tissues\(^6,11\). In support of this suggestion, the inactivation-resistant analogue methanandamide inhibited pain behaviour during the entire test (Fig. 1a).

Local anandamide injections were not accompanied by central signs of cannabinimimetic activity, indicating a peripheral site of action. To test this possibility, we measured the antinociceptive potency of anandamide following local (intraplantar, i.pl.), intravenous (i.v.) or intraperitoneal (i.p.) administrations. Anandamide was 100 times more potent in preventing formalin-evoked pain behaviour when injected locally rather than intravenously, with half-maximal inhibitory doses (ID\(_{50}\) values) of 0.1 mg per kg and 10 mg per kg, respectively (Fig. 1b). Anandamide had no significant effect when injected intraperitoneally (Fig. 1b). As a further test, we determined the biodistribution of \(^3\)H-labelled anandamide 10 min after i.pl. injection in rats. In three experiments, we found that 94% of recovered \(^3\)H-labelled anandamide remained associated with the injected paw (6648 ± 820 d.p.m. per g, mean ± s.e.m.), whereas little or no radioactivity above background was detected in forebrain, cerebellum and spinal cord (79 ± 19, 165 ± 67 and 90 ± 48 d.p.m. per g, respectively). These results indicate that anandamide inhibits nociception after formalin injection by activating CB1-like receptors, which may be located on peripheral endings of sensory neurons involved in pain transmission\(^5,6\).

Anandamide is the ethanolamid of arachidonic acid and is thought to be produced by phosphodiesterase-mediated cleavage of N-arachidonyl phosphatidylyethanolamine\(^19\). Enzymatic cleavage of other N-acyl phosphatidyethanolamines may give rise to additional fatty acylethanolamides, the physiological roles of which are still poorly understood\(^22\). PEA, an acylethanolamide found in neural and non-neural tissues, inhibits mast-cell activation and reduces inflammatory responses\(^21,22\) by a mechanism that may involve binding to CB2-like receptors\(^25\). The molecular identity of these receptors is unknown, although they are likely to be distinct from the CB2 receptors whose encoding genes have been cloned, as PEA shows little or no affinity for these receptors\(^23\). We found that PEA, but not two closely related analogues, inhibited both early and late phases of formalin-evoked pain behaviour after i.pl. injection in mice (Fig. 2a). This effect may not be explained by the anti-inflammatory properties of PEA; 30 min after injection, the analgesic effects of PEA were not accompanied by a reduction in inflammatory oedema (volumes injected into the paw in ml were: control, 0.18 ± 0.003; formalin, 0.37 ± 0.006; formalin plus 50 µg PEA, 0.35 ± 0.006), which became apparent only 1 h after formalin administration\(^21\).

The analgesia produced by PEA was reversed by administration of the CB2 antagonist SR144528 (Fig. 2a), whereas the CB1 antagonist SR141716A and the opioid antagonist naloxone were ineffective (Fig. 2a; data not shown). In addition, PEA was more potent when administered locally (i.pl.) than systemically (i.v. or i.p.) (Fig. 2b). Together, these results indicate that PEA exerts antinociceptive

---

**Figure 1** Anandamide inhibits formalin-evoked nociception by activating peripheral CB1-like cannabinoid receptors. **a**, Effects of anandamide (AEA, 50 µg i.pl.), WIN-55212-2 (WIN, 500 µg i.pl.) and methanandamide (MAEA, 50 µg i.pl.), in the absence or presence of the CB1 antagonist SR141716A (SR1, 0.1 mg per kg i.v.) or the CB2 antagonist SR144528 (SR2, 0.1 mg per kg i.v.). Open columns represent the early phase and filled columns the late phase of formalin-evoked nociception. Asterisk indicates \(P < 0.01\) (\(n = 12-18\) for each condition). **b**, Dose-dependent antinociceptive effects of anandamide following i.pl. (squares), i.v. (triangles) or i.p. (circles) administration.

**Figure 2** PEA inhibits formalin-evoked nociception by activating peripheral CB2-like cannabinoid receptors. **a**, Effects of PEA (50 µg i.pl.), stearylethanolamide (SEA, 50 µg i.pl.) and oleylethanolamide (OEA, 50 µg i.pl.), in the absence or presence of the CB1 antagonist SR141716A (SR1, 0.1 mg per kg i.v.) or the CB2 antagonist SR144528 (SR2, 0.1 mg per kg i.v.). Open columns represent the early phase and filled columns the late phase of formalin-evoked nociception. Asterisk indicates \(P < 0.01\) (\(n = 12-18\)). **b**, Dose-dependent antinociceptive effects of PEA following i.pl. (squares), i.v. (triangles) or i.p. (circles) administration.
effects that are mediated by peripheral CB2-like receptors. The cellular localization of such receptors and their possible structural relationship with the CB2 receptor whose gene has been cloned, which is primarily expressed in immune cells\(^5\), are unknown.

The fact that anandamide and PEA activate pharmacologically distinct receptors and that these two substances can be produced simultaneously in tissues\(^6\) prompted us to examine their possible interactions *in vivo*. When injected together in equal amounts, anandamide and PEA inhibited the early phase of formalin-evoked pain behaviour with a potency that was approximately 100-fold greater than each of the compounds separately (Fig. 3a). A similar synergistic potentiation occurred in the late phase, on which anandamide had no effect when given alone (Figs 1a and 3b). Earlier administration of either CB1 or CB2 antagonists entirely blocked the response (Fig. 3c). This interaction did not appear to involve pain-processing structures within the brain: injection of PEA in the cerebral ventricles did not affect the behavioural responses to acute thermal stimuli, assessed in the hot-plate test, and did not enhance the inhibitory activity of anandamide administered by the same route (Table 1). These results indicate that the parallel activation of peripheral CB1- and CB2-like receptors by anandamide and PEA results in a synergistic inhibition of peripheral pain initiation.

To test this idea further, we determined the intrinsic effects of CB1 and CB2 antagonists on formalin-evoked pain behaviour (Fig. 4). Blockade of CB1 receptors with SR141716A produced significant hyperalgesia (Fig. 4a)\(^7\). This effect was particularly pronounced after local injection of the drug, which resulted in a 10-min prolongation of the early nociceptive phase and in a two- to threefold increase in pain behaviour during the entire testing period (Fig. 4b). In contrast, systemic administration of the CB2 antagonist SR144528 caused a selective enhancement of early-phase, but not of late-phase, responses (Fig. 4a). The selectivity of this effect may not result from a rapid elimination of SR144528 after early phase, as the drug reversed PEA-induced antinociception during both early- and late-phase pain behaviour (Fig. 2). SR144528 could not be administered locally because of its limited solubility in the injection vehicle.

Although the hyperalgesic effects of CB1 and CB2 antagonists may be accounted for by their inverse agonist properties\(^8,25\), two lines of evidence suggest that these drugs acted by removing an endogenous cannabinoid tone. First, gas-chromatography/mass-spectrometry analyses showed that anandamide and PEA are present in

---

**Figure 3** Anandamide and PEA synergistically inhibit formalin-evoked nociception. a, Early phase. b, Late phase (open squares, anandamide; filled diamonds, PEA; filled circles, anandamide plus PEA). Equal amounts of anandamide and PEA were administered by i.pl. injection at the doses indicated on the abscissa. c, The CB1 antagonist SR141716A (SR1) and the CB2 antagonist SR144528 (SR2) prevent the effects of anandamide plus PEA (0.1 µg each of anandamide and PEA). Open columns represent the early phase and closed columns the late phase of formalin-evoked nociception. Antagonists were administered by i.v. injection at the dose of 0.1mg per kg. Asterisk denotes \(P < 0.01 (n = 12)\).

---

**Figure 4** Intrinsic hyperalgesic effects of cannabinoid antagonists on the time course of formalin-evoked nociception. a, Effects of systemic administration of the CB1 antagonist SR141716A (filled bars) and the CB2 antagonist SR144528 (grey shaded bars). The drugs were administered by i.v. injection at 0.1mg per kg. The responses to formalin alone are shown by open bars. b, Effects of local administration of SR141716A (filled bars). 10µg of SR141716A were administered with formalin by i.pl. injection. SR144528 was not soluble in 10% DMSO, and could not be injected locally. Asterisk denotes \(P < 0.01 (n = 6)\).
rat paw skin (Fig. 5). By comparison with internal deuterated standards, we measured 49 ± 9 pmol of anandamide and 692 ± 119 pmol of PEA per g of tissue (n = 8). These amounts are five- to tenfold higher than those measured by the same method in rat brain and plasma22,23, and are probably sufficient to activate cannabinoid receptors24. Second, the CB2 antagonist SR144528 enhanced nociception selectively during the early phase of the formalin response (Fig. 4a), a result inconsistent with an inverse agonist effect. Thus, a parsimonious interpretation of our findings is that endogenous PEA acting at CB2-like receptors may participate in attenuating the early stages of nociception, whereas endogenous anandamide acting at CB1-like receptors may have a more sustained modulatory effect on both acute and tonic pain.

Our results show that the tonic activation of local CB1-like and CB2-like receptors may regulate pain initiation in cutaneous tissue. These findings support the possibility that endogenous cannabinoids, in addition to their spinal and supraspinal sites of action4, may participate in buffering emerging pain signals at sites of tissue injury. The results also indicate that selective agonists for the CB2-like receptor activated by PEA, or peripherally administered CB1-like/CB2-like agonists, may reduce pain without the dysphoric side effects and perceived abuse potential typical of centrally acting cannabinimetic or opiate drugs.

Note added in proof: After submission of this paper, Jaggar et al.29 have observed an analgesic effect of systemically administered PEA in formalin-induced pain.

Methods

Drugs. Anandamide, PEA, stearylthanolamide and oleylethanolamide were synthesized following standard procedures2; SR144528 [N-[(1S)-endo-1, 3, 3-trimethyl bicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide] was a gift from Sanofi; SR141716A [[N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide·HCl]] was provided by RBI as part of the Chemical Synthesis Program of the NIMH; all other drugs were from Tocris. The drugs were dissolved in dimethylsulphoxide (DMSO) and administered in physiologically saline containing 10% DMSO; volumes injected were 0.2 ml i.v. and i.p. and 0.01 ml i.pl.

Nociceptor tests. Saline (10 µl) containing 5% formalin and 10% DMSO was injected subcutaneously into the hind paws of male Swiss mice (20–25 g in weight; Nossan). The duration of paw licking was monitored by an observer blind to the experimental treatment for periods of 0–15 min (early phase) and 15–30 min (late phase) after formalin administration. Initial tests determined that the presence of 10% DMSO in the injection vehicle did not significantly affect formalin responses (data not shown). For the experiment in Fig. 4, pain behaviour was monitored for 5-min periods during the 30 min following formalin injection. Time delays to escape jumping or hind-paw licking were measured on a plate heated to 55.5 °C, according to standard procedures25.

Inflammation. Inflammatory oedema was induced by injecting saline (10 µl) containing 5% formalin and 10% DMSO, and were measured with a plethysmometer26 (Ugo Basile).

Gas chromatography/mass spectrometry (GC/MS). Hairless paw skin tissue was excised from Wistar rats anaesthetized with nembutal, and immediately immersed in cold methanol to prevent alterations in tissue lipids. After homogenization and chloroform/methanol extraction, high-performance liquid chromatography and quantitative analysis of the trimethyl silyl derivatives of anandamide and PEA by isotope dilution GC/MS were carried out as described27.

Data analysis. Results are expressed as means ± s.e.m. The significance of differences between groups was evaluated using analysis of variance with a subsequent Dunnett's test.

Received 19 January; accepted 20 April 1998.

1. Martin, B. R., Balster, R. L., Razdan, R. K., Harris, L. S. & Desry, W. L. Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci. 20, 565–574 (1981).
2. Martin, W. L., Lai, N. K., Patrick, S. L., Tsou, K. & Walker, J. M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629, 300–304 (1993).
3. Tsou, K. et al. Suppression of noxious stimulus-evoked expression of FOS protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 70, 791–798 (1996).
4. Lichtman, A. H., Cook, S. A. & Martin, B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276, 585–593 (1996).
5. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932–1936 (1990).
6. Tsou, K., Brown, S., Saffredo-Peña, M. C., Mackie, K. & Walker, J. M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393–410 (1998).
7. Devane, W. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992).
8. Richardson, J. D., Aaenosen, L. & Hargreaves, K. M. Hypoactivity of the spinal cannabinoid system in an NMDA-dependent hyperalgesia model. F. Neuroan 18, 451–457 (1998).
9. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686–691 (1994).
10. Fields, H. L. Pain (McGraw-Hill, New York, 1987).
11. Stein, C. The control of pain in peripheral tissue by opioids. New Engl. J. Med. 332, 1685–1690 (1995).
12. Dubuisson, D. & Dennis, S. G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4, 161–174 (1977).
13. Dickerson, A. H. & Sullivan, A. F. Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intraplantar opiate administered pre or post formalin. Pain 30, 369–380 (1987).
14. Rodland, I. H., Tjølsen, A., Mæhle, B. & Hole, K. The formalin test in mice: effect of formalin concentration. Pain 42, 235–242 (1990).
15. Greder, T. J. & Melzack, R. The contribution of excitatory amino acids to central sensitization and antinociception after formalin-induced tissue injury. J. Neurosci. 12, 3665–3670 (1992).
16. Rinaldi-Carmona, M. et al. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644–650 (1998).
17. Cравat, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87 (1996).
18. Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094–1097 (1997).
19. Cadas, H., di Tommaso, E. & Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17, 1226–1242 (1997).
20. Schmid, H. H., O., Schmid, P. C. & Narassaj, V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 80, 133–142 (1996).
21. Aloe, L., Leon, A. & Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39, C145–C147 (1993).
22. Mazzoli, S., Canello, R., Petrelli, L., Marcolongo, G. & Leon, A. N-[(2-hydroxyethyl)hexadecanamide is orally-active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300, 227–236 (1996).
23. Facci, L. et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl Acad. Sci. USA 92, 3376–3380 (1995).
24. Showalter, V. M., Compton, D. R., Martin, B. R. & Aboud, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 988–999 (1996).
25. Muñoz, S., Thomas, K. I. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65 (1993).
27. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term responses of expressed, developmental, auditory potentials how the authors evidence. FEBS Lett., 242, 373–376 (1988).

28. Jagger, S. I., Hasnie, F. S., Sellartay, S. & Rice, A. S. C. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain (in the press).

Acknowledgements. We thank P. Ciniminelli, F. De Seta and V. Piccioni for experimental assistance, and M. Berramos, A. Makriyannis, L. Sorrentino and N. Stella for discussion. Supported by Neurosciences Research Foundation (A.G. and D.P.), which receives major support from Novartis, and by MURST (G.L.R. and A.C.).

Correspondence and requests for materials should be addressed to D.P. (e-mail: piomelli@msi.edu).

Expression of a potassium current in inner hair cells during development of hearing in mice

Corné J. Kros†‡, J. Peter Ruppersberg§§ & Alfonso Rüsch†‡§

† Department of Physiology, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK
‡ School of Biological Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK
§ Department of Physiology, University of Tübingen, Gmelinstraße 5, 72076 Tübingen, Germany
§§ Division of Sensory Biophysics, ENT Hospital, University of Tübingen, Röntgenweg 11, 72076 Tübingen, Germany

† These authors contributed equally to this work.

Excitable cells use ion channels to tailor their biophysical properties to the functional demands made upon them. During development, these demands may alter considerably, often associated with a change in the cells’ complement of ion channels. Here we present evidence for such a change in inner hair cells, the primary sensory receptors in the mammalian cochlea. In mice, responses to sound can first be recorded from the auditory nerve and observed behaviourally from 10–12 days after birth; these responses mature rapidly over the next 4 days. Before this time, mouse inner hair cells have slow voltage responses and fire spontaneously and evoked action potentials. During development of auditory responsiveness a large, fast potassium conductance is expressed, greatly speeding up the membrane time constant and preventing action potentials. This change in potassium channel expression turns the inner hair cell from a regenerative, spiking pacemaker into a high-frequency signal transducer.

Substantial changes in the ear’s anatomy and in gross cochlear potentials occur around the onset and subsequent rapid maturation of auditory function. Very little is known, by contrast, about how the membrane currents of the inner and outer hair cells (IHCs and OHCs) develop. We have studied, under whole-cell voltage clamp, time- and voltage-dependent conductances of IHCs, the cells responsible for signaling the reception of sound to the brain, as a function of development between postnatal day (P) 0 and 68.

Before P11–P12, the outward membrane currents of IHCs rise slowly and are fairly small (Fig. 1a). By P13, the outward currents of all cells have acquired an additional fast component (Fig. 1b) which becomes larger over the next few days, as shown for a P19 cell in Fig. 1c. The current—voltage curves of Fig. 1d (filled symbols) show the appearance and the increase in magnitude of the fast component of the outward current that occurs between P11 and P19; this fast component is largely responsible for the increase in total current (open symbols).

The outward currents recorded in mouse IHCs from a few days after the onset of hearing closely resemble the membrane currents described before for mature guinea-pig IHCs, which also have a fast and a slow component equated with two different potassium currents, $I_{Ks}$ (probably carried by BK channels$^{1,12,13}$) and $I_{Ka}$ (a delayed rectifier, r respectively$^{1,12,13}$). The fast component of the current in mouse IHCs is reversibly suppressed by tetraethylammonium (TEA; half-blocking concentration ($IC_{50}$) estimated from the dose–response curve as 0.30 ± 0.03 mM; n = 5), to which the slow component is comparatively resistant ($IC_{50}$ = 31 ± 8 mM; n = 4; measured between P17 and P20). The fast component is also blocked by charybdotoxin with an $IC_{50}$ of 21 ± 2 nM (n = 13) and by the apparently selective BK-channel-blocker iberiotoxin$^{16}$ ($IC_{50} < 10$ nM; n = 3). Taken together, these evidence identifies the fast component in mouse IHCs with $I_{Ka}$. The slow component of the mouse $K^+$ currents is like $I_{Ks}$ in cells studied after the onset of hearing, but the slow current observed at earlier times, in neonatal cells, appears different$^{15}$: it inactivates (slowly) and is considerably more sensitive to block by TEA ($IC_{50}$ 4.6 ± 0.9 mM, n = 6; P4–P11); we therefore call it $I_{Kwa}$. The development over time of the different currents is shown in Fig. 2. The total current increases sevenfold between P12 and P16 (Fig. 2a), coincident with the onset and rapid maturation of hearing. Figure 2b shows that this increase is not simply due to the increase in cell capacitance (or membrane area), which is less than twofold, and has a different time course. The increase in total current is mostly contributed by the appearance of $I_{Kwa}$ (Fig. 2c): there is an increase in the slow current as well, but it is more gradual (Fig. 2d). In the maturing cochlea, develop-